INTRODUCTION

METHODS
RESULTS
■ While the benefit of statins for reducing CV morbidity and mortality in patients with dyslipidaemia is well established, some patients develop SI due to adverse effects (AEs) including muscle aches and weakness, gastrointestinal (GI) symptoms, liver enzyme abnormalities, or other nonspecific complaints. 1 ■ SI is reported in 5%-10% of subjects in randomized, placebo-controlled trials, and up to 20% in observational studies. 1 ■ In patients with dyslipidaemia, SI can lead to statin discontinuation or dose reduction sufficient to prevent patients from reaching target low-density lipoprotein cholesterol (LDL-C)
Study design
■ This was a non-interventional, observational, retrospective, longitudinal, healthcare database study.
Data source
■ Analyses were conducted using data from the proprietary Southwestern Ontario (SWO) Primary Care Practice Database (Individual Health Outcomes, Inc.), which contains longitudinal healthcare resource utilization and outcomes data for >330,000 adult patients, contributed by >100 participating physicians at >70 primary practices. ■ All patient records in the SWO database are anonymized to conform to current confidentiality regulations. Table 1 . ■ Patients were stratified into three CV risk levels (Table 2) .
Patient selection
Patient characteristics
■ A total of 41,733 patients who initiated statin therapy were included, of whom 14,607 (35%) were high-risk patients and 1294 (9% of high-risk patients) had SI. ■ Patient characteristics at the SI index date are shown in Table 3 .
At baseline in the high-risk group, the mean (SD) age was 61 (8.9) years, 53% were male, and mean (SD) LDL-C was 2.8 (
■ Maintaining the same statin dose after the first SI event was more common in patients on LDL-C target vs. those not on LDL-C target 6 months after the first SI event: 28% vs 7%, respectively (Table 4 ). ■ Among the 636 patients not on LDL-C target at 6 months post-SI, 279 (44%) were switched to a non-statin therapy (primarily fibrates); in contrast, no patients on LDL-C target at 6 months post-SI switched to a non-statin.
■ In the high-risk group, the SI incidence rate (95% CI) was 125.23 (118.50, 132.24) per 10,000 person-years. ■ At the SI index date 84% (n=1085) of patients had achieved the LDL-C target according to contemporaneous Canadian Cardiovascular Society guidelines, with the on-target proportion decreasing to 49% (n=638) 6 months post-SI.
■ There were nine rhabdomyolysis cases, two resulting in hospitalization and seven treated in outpatient clinics. ■ Weakness and fatigue were over twice as common as the next-most-frequent symptom, joint pain.
Management of statin intolerance
■ Of the 1294 high-risk patients with SI, 412 (32%) discontinued statin therapy and 677 (52%) had a dose decrease (Table 4) .
Outcomes of interest
■ This presentation focuses on the incidence and management of SI in the CV high-risk patient group. 
Statistical analysis
■ Descriptive statistics are presented: mean, standard deviation (SD), confidence interval (CI), and percentage. 
Frequency of statin intolerance symptoms
■ Among the 1294 patients identified with SI, 170 (13%) experienced myopathy and 1124 (87%) had other SI-related symptoms ( Figure 1 ).
